- Home
- FORA vs CRVO Comparison
FORA vs CRVO Comparison
Compare FORA & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- CRVO
- Stock Information
- Founded
- FORA 2014
- CRVO 2001
- Country
- FORA United States
- CRVO United States
- Employees
- FORA N/A
- CRVO N/A
- Industry
- FORA Computer Software: Prepackaged Software
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- CRVO Health Care
- Exchange
- FORA Nasdaq
- CRVO Nasdaq
- Market Cap
- FORA 69.4M
- CRVO 67.4M
- IPO Year
- FORA N/A
- CRVO N/A
- Fundamental
- Price
- FORA $2.24
- CRVO $7.05
- Analyst Decision
- FORA Strong Buy
- CRVO Strong Buy
- Analyst Count
- FORA 1
- CRVO 6
- Target Price
- FORA $5.00
- CRVO $19.17
- AVG Volume (30 Days)
- FORA 389.0K
- CRVO 105.0K
- Earning Date
- FORA 11-11-2025
- CRVO 11-12-2025
- Dividend Yield
- FORA N/A
- CRVO N/A
- EPS Growth
- FORA N/A
- CRVO N/A
- EPS
- FORA N/A
- CRVO N/A
- Revenue
- FORA $25,031,040.00
- CRVO $7,776,968.00
- Revenue This Year
- FORA $47.82
- CRVO N/A
- Revenue Next Year
- FORA $10.11
- CRVO N/A
- P/E Ratio
- FORA N/A
- CRVO N/A
- Revenue Growth
- FORA 18.59
- CRVO N/A
- 52 Week Low
- FORA $1.64
- CRVO $1.80
- 52 Week High
- FORA $4.03
- CRVO $16.94
- Technical
- Relative Strength Index (RSI)
- FORA 50.12
- CRVO 40.09
- Support Level
- FORA $2.11
- CRVO $6.70
- Resistance Level
- FORA $2.41
- CRVO $7.30
- Average True Range (ATR)
- FORA 0.13
- CRVO 0.40
- MACD
- FORA -0.00
- CRVO -0.02
- Stochastic Oscillator
- FORA 36.11
- CRVO 20.78
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.